Head and Neck Cancer SPORE at the University of Wisconsin

项目总结 威斯康星州的头颈部孢子旨在促进实验室和临床研究的转化 改善头颈癌(HNC)患者的整体预后。这一高度协作的研究链接 基础科学家与HNC临床医生合作，为这一复杂的癌症人群提出新的治疗策略。 根据肿瘤的关键解剖位置，这些患者承受着不成比例的癌症负担。 这种疾病的治疗可以损害语言、吞咽和呼吸功能，除了 身体外貌和社交能力的显著变化。努力提高治愈率 必须谨慎地平衡减少治疗毒性的努力，以提高 病人。这个孢子的广泛目标是：1)促进HNC的多学科翻译研究， 2)改善HNC患者的总体生存和生活质量，3)结合新的预测模型进行测试 新的HNC治疗策略，4)提高对免疫调节如何增强的理解 HNC的常规和实验治疗反应，5)翻译开发的有前途的新分子 在威斯康星大学和工业界通过临床前试验和进入HNC临床试验。这个 威斯康星州HN孢子设计了三个初步研究项目。项目1将结合目标 具有免疫检查点抑制(ICI)的放射性核素疗法(TRT)刺激增强的HNC反应 在I期临床试验中达到顶峰的概况。项目2构建了一个强大的针对患者的生物工程HNC 从患者细胞到更准确地结合肿瘤微环境成分的模型系统 预测HNC患者的治疗反应。使用模型中的治疗反应数据的可行性 通知术后放射治疗将在临床先导研究中进行测试。项目3研究了双重目标 关键受体酪氨酸激酶Ax1和MerTK介导免疫微环境和 从而增强HNC患者的肿瘤反应。威斯康星州的孢子将用三个支持这项研究 CORES(行政、病理学和生物统计学)、职业提升计划和发展计划 研究计划。

PROJECT SUMMARY The Wisconsin Head and Neck SPORE is designed to promote translational laboratory and clinical research to improve overall outcome for patients with Head and Neck Cancer (HNC). This highly collaborative research links basic scientists with HNC clinicians to advance novel treatment strategies for this complex cancer population. These patients bear a disproportionate burden from their cancers based on the critical anatomic location of the disease for which treatment can compromise speech, swallow, and breathing function, in addition to creating significant alterations in physical appearance and capacity for social interaction. Efforts to improve cure rates must be carefully balanced with efforts to reduce treatment toxicity to enable enhanced overall quality of life for patients. The broad objectives of this SPORE are to: 1) Promote multidisciplinary translational research in HNC, 2) Improve overall survival and quality of life for patients with HNC, 3) Incorporate new predictive models to test novel HNC treatment strategies, 4) Improve understanding of how immune modulation can augment conventional and experimental treatment responses in HNC, 5) Translate promising new molecules developed at the University of Wisconsin and from Industry through preclinical testing and into HNC clinical trials. The Wisconsin HN SPORE has designed three primary research projects. Project 1 will combine targeted radionuclide therapies (TRT) with immune checkpoint inhibition (ICI) to stimulate enhanced HNC response profiles culminating in a Phase I clinical trial. Project 2 builds a powerful patient-specific bioengineered HNC model system from patient cells that incorporates components of the tumor microenvironment to more accurately predict HNC patient treatment response. The feasibility of using treatment response data from the model to inform postoperative radiation therapy will be tested in a clinical pilot study. Project 3 examines dual targeting of critical receptor tyrosine kinases Axl and MerTK to mediate changes in the immune microenvironment and thereby augment tumor response in HNC patients. The Wisconsin SPORE will support this research with three Cores (Administrative, Pathology and Biostatistics), a Career Enhancement Program and a Developmental Research Program.